Initiate Phase 3 trial of SY-1425 in combination with azacitidine
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate Phase 3 trial of SY-1425 in combination with azacitidine in the first quarter of 2021”
What we found
Evidence strength A What the grades mean
The company confirmed in an 8-K filing that the Phase 3 trial for SY-1425 in combination with azacitidine was initiated in the first quarter of 2021.
-
A Syros Pharmaceuticals, Inc. 8-K filed 2021-05-26
“Key Milestones Trial initiated 1Q 2021” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Merger
- Indicative materiality
- Transformational rules
- Action
- Initiate
- Deliverable
- Phase 3 trial of SY-1425
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Syros Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C556263-021608 · Corrections policy